论文部分内容阅读
目的对比观察厄贝沙坦与依那普利治疗轻中度原发性高血压的疗效和安全性。方法随机观察厄贝沙坦(41例,150mg～300mg)与依那普利(42例,10～20mg)治疗高血压患者4周和8周的有效率,并分两组进行比较。结果两组治疗第2周后开始平均收缩压、舒张压较治疗前明显降低(P<0.01),在整个治疗期间血压持续平稳下降;厄贝沙坦与依那普利治疗4周降低舒张压总有效率分别为90.2%(37/41)和83.3%(35/42),8周降低舒张压总有效率分别为95.1%(39/41)和90.5%(38/42),两组比较P>0.05。结论厄贝沙坦是一安全、有效、长效,耐受性好,不良反应轻的降压药物。
Objective To compare the efficacy and safety of irbesartan and enalapril in the treatment of mild to moderate essential hypertension. Methods The efficacy of irbesartan (41 cases, 150mg ~ 300mg) and enalapril (42 cases, 10 ~ 20mg) were observed at 4 weeks and 8 weeks in patients with hypertension. Results The average systolic blood pressure began to decrease after 2 weeks of treatment in both groups, and the diastolic blood pressure was significantly lower than that before treatment (P <0.01). The blood pressure continued to decrease steadily throughout the treatment period. Diastolic blood pressure was decreased by irbesartan and enalapril treatment for 4 weeks The total effective rates were 90.2% (37/41) and 83.3% (35/42), respectively. The total effective rates of reducing diastolic blood pressure after 8 weeks were 95.1% (39/41) and 90.5% (38/42), respectively P> 0.05. Conclusion Irbesartan is a safe, effective, long-acting, well tolerated, adverse reactions light antihypertensive drugs.